Home > Cardiology > ACC 2022 > Prevention > RCT-IVVE trial: Do HF patients benefit from annual flu shots?

RCT-IVVE trial: Do HF patients benefit from annual flu shots?

Presented By
Prof. Mark Loeb, McMaster University, Canada
Conference
ACC 2022
Trial
Phase 4, RCT-IVVE
Major cardiovascular events were not significantly reduced in patients with heart failure (HF) who received an annual influenza vaccine compared with those who had not received an annual flu shot. Although the primary endpoint of the IVVE trial was not met, the authors argued that other findings of the trial suggest that administrating an annual influenza vaccine in this population offers clinical benefits. The phase 4 RCT-IVVE trial (NCT02762851) randomised 5,129 patients with HF from Asia, Africa, and the Middle East to receive an annual influenza vaccine or a placebo shot [1]. The first primary endpoint of the study was a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. The second primary endpoint added HF hospitalisation to the composite outcome of the first primary outcome. After 3 years, the first primary outcome had o...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on